CheckMate 227 trialVeröffentlicht am: 28. Sept. 2019
ESMO 2019: Immunotherapy drug combination offers chemo-free option for advanced NSCLC
First-line treatment with nivolumab plus low-dose ipilimumab improves overall survival in a subset of patients with advanced NSCLC compared to chemotherapy.
